Ninghua Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ninghua Yao has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hongyu Zhao
Affiliated Hospital of Nantong University
2 shared publications Jie Sun
2 shared publicationsWei Jiang
Department of Neurology, the Second People's Hospital of Wuxi, Wuxi, China
2 shared publicationsWenjie Zheng
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
2 shared publicationsYumeng Shi
2 shared publicationsChen Yang
Shanghai Cancer Institute
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 7329-7346
Radiomics-based machine learning for glioma grade classification: a multicenter study with SHapley Additive exPlanations interpretability analysis
Background: The accurate preoperative grading of gliomas is critical for guiding therapeutic strategies and prognostic assessment. This study aimed to develop and validate a robust, interpretable machine learning (ML) model based on multicenter magnetic resonance imaging (MRI) radiomics data for predicting the World Health Organization (WHO) grade in glioma patients. Methods: We collected MRI data from 905 glioma patients diagnosed between 2005–2024 across three independent cohorts. Data from 329 of The Cancer Genome Atlas (TCGA) patients served as training (n=230) and internal testing (n=99) sets, while data from 482 University of California San Francisco (UCSF) patients and 94 Nantong University Affiliated Hospital (NTUA) patients served as external validation sets. Radiomics features were extracted from preoperative T1-weighted contrast-enhanced MRI. Ten ML methods, including extreme gradient boosting (XGBoost), were compared using recursive feature elimination (RFE) with cross-validation. The SHapley Additive exPlanation (SHAP) method was used for the model interpretability analysis. Results: Among the 10 ML models, XGBoost performed best with area under the curve (AUC) values of 0.983 [95% confidence interval (CI): 0.968–0.996] in the training set, 0.897 (95% CI: 0.836–0.956) in the internal testing set, and 0.834 (95% CI: 0.766–0.883) in the UCSF cohort and 0.880 (95% CI: 0.771–0.974) in the NTUA cohort. The model achieved an accuracy of 82.3–94.3%, significantly outperforming conventional imaging assessment. The calibration analysis showed excellent agreement (Hosmer-Lemeshow P>0.05) with a maximum net benefit of 0.42. The SHAP analysis identified 12 optimal features, primarily texture heterogeneity measures from Laplacian of Gaussian (LoG) and wavelet transforms, as key predictors of glioma grade. Conclusions: We successfully developed and validated a robust, interpretable radiomics-based model that accurately predicts glioma WHO grade preoperatively. Its promising performance across diverse datasets suggests potential for clinical translation, though prospective validation in real-world clinical workflows is required to confirm clinical utility and assess impact on treatment decisions and patient outcomes.
- 1 October 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 7329-7346
Open AccessRadiomics-based machine learning for glioma grade classification: a multicenter study with SHapley Additive exPlanations interpretability analysis
Background: The accurate preoperative grading of gliomas is critical for guiding therapeutic strategies and prognostic assessment. This study aimed to develop and validate a robust, interpretable machine learning (ML) model based on multicenter magnetic resonance imaging (MRI) radiomics data for predicting the World Health Organization (WHO) grade in glioma patients. Methods: We collected MRI data from 905 glioma patients diagnosed between 2005–2024 across three independent cohorts. Data from 329 of The Cancer Genome Atlas (TCGA) patients served as training (n=230) and internal testing (n=99) sets, while data from 482 University of California San Francisco (UCSF) patients and 94 Nantong University Affiliated Hospital (NTUA) patients served as external validation sets. Radiomics features were extracted from preoperative T1-weighted contrast-enhanced MRI. Ten ML methods, including extreme gradient boosting (XGBoost), were compared using recursive feature elimination (RFE) with cross-validation. The SHapley Additive exPlanation (SHAP) method was used for the model interpretability analysis. Results: Among the 10 ML models, XGBoost performed best with area under the curve (AUC) values of 0.983 [95% confidence interval (CI): 0.968–0.996] in the training set, 0.897 (95% CI: 0.836–0.956) in the internal testing set, and 0.834 (95% CI: 0.766–0.883) in the UCSF cohort and 0.880 (95% CI: 0.771–0.974) in the NTUA cohort. The model achieved an accuracy of 82.3–94.3%, significantly outperforming conventional imaging assessment. The calibration analysis showed excellent agreement (Hosmer-Lemeshow P>0.05) with a maximum net benefit of 0.42. The SHAP analysis identified 12 optimal features, primarily texture heterogeneity measures from Laplacian of Gaussian (LoG) and wavelet transforms, as key predictors of glioma grade. Conclusions: We successfully developed and validated a robust, interpretable radiomics-based model that accurately predicts glioma WHO grade preoperatively. Its promising performance across diverse datasets suggests potential for clinical translation, though prospective validation in real-world clinical workflows is required to confirm clinical utility and assess impact on treatment decisions and patient outcomes.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2357-2376
The SNHG3/miR-148a-3p axis-mediated high expression of DNMT1 is correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma
Background: Epigenetic reprogramming, particularly DNA methylation mediated by DNA-methyltransferase 1 (DNMT1), plays a crucial role in the pathogenesis of hepatocellular carcinoma (HCC). However, the regulatory mechanisms underlying DNMT1 overexpression and its relationship with immune infiltration in HCC remain unclear. This study aimed to investigate the expression pattern, prognostic significance, and regulatory network of DNMT1 in HCC, as well as its correlation with the tumor immune microenvironment. Methods: A pan-cancer analysis of DNMT1 expression and prognosis was conducted using The Cancer Genome Atlas (TCGA) data. A cohort of 102 pairs of HCC and adjacent normal tissues from patients who underwent surgical resection was analyzed by immunohistochemistry (IHC). Upstream regulatory non-coding RNAs (ncRNAs) were identified by bioinformatics analyses, including an expression correlation analysis, survival analysis, and competing endogenous RNA (ceRNA) network construction. The relationship between DNMT1 expression and immune cell infiltration was evaluated using multiple algorithms, including TIMER, CIBERSORT, and xCell. A Gene Set Enrichment Analysis (GSEA) was performed to identify the DNMT1-associated functional pathways. Results: DNMT1 was significantly overexpressed in the HCC tissues compared to the normal control tissues, and was correlated with poor overall survival (OS) and relapse-free survival (RFS). High DNMT1 expression was associated with advanced histological grade, elevated alpha-fetoprotein (AFP) levels, and older age (P+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells (DCs). Moreover, DNMT1 expression was significantly positively correlated with immune checkpoint molecules, including programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4). The GSEA results revealed that high DNMT1 expression was enriched in epithelial-mesenchymal transition (EMT), E2F targets, the G2M checkpoint, and inflammatory response pathways. Conclusions: The SNHG3/miR-148a-3p/DNMT1 axis represents a novel regulatory pathway in hepatocarcinogenesis. DNMT1 overexpression could serve as a biomarker for poor prognosis, and is closely associated with enhanced immune cell infiltration and immune checkpoint expression in HCC. These findings suggest that DNMT1 may serve as a potential therapeutic target for both conventional treatment and immunotherapy in HCC patients.
- 1 October 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2357-2376
Open AccessThe SNHG3/miR-148a-3p axis-mediated high expression of DNMT1 is correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma
Background: Epigenetic reprogramming, particularly DNA methylation mediated by DNA-methyltransferase 1 (DNMT1), plays a crucial role in the pathogenesis of hepatocellular carcinoma (HCC). However, the regulatory mechanisms underlying DNMT1 overexpression and its relationship with immune infiltration in HCC remain unclear. This study aimed to investigate the expression pattern, prognostic significance, and regulatory network of DNMT1 in HCC, as well as its correlation with the tumor immune microenvironment. Methods: A pan-cancer analysis of DNMT1 expression and prognosis was conducted using The Cancer Genome Atlas (TCGA) data. A cohort of 102 pairs of HCC and adjacent normal tissues from patients who underwent surgical resection was analyzed by immunohistochemistry (IHC). Upstream regulatory non-coding RNAs (ncRNAs) were identified by bioinformatics analyses, including an expression correlation analysis, survival analysis, and competing endogenous RNA (ceRNA) network construction. The relationship between DNMT1 expression and immune cell infiltration was evaluated using multiple algorithms, including TIMER, CIBERSORT, and xCell. A Gene Set Enrichment Analysis (GSEA) was performed to identify the DNMT1-associated functional pathways. Results: DNMT1 was significantly overexpressed in the HCC tissues compared to the normal control tissues, and was correlated with poor overall survival (OS) and relapse-free survival (RFS). High DNMT1 expression was associated with advanced histological grade, elevated alpha-fetoprotein (AFP) levels, and older age (P+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells (DCs). Moreover, DNMT1 expression was significantly positively correlated with immune checkpoint molecules, including programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4). The GSEA results revealed that high DNMT1 expression was enriched in epithelial-mesenchymal transition (EMT), E2F targets, the G2M checkpoint, and inflammatory response pathways. Conclusions: The SNHG3/miR-148a-3p/DNMT1 axis represents a novel regulatory pathway in hepatocarcinogenesis. DNMT1 overexpression could serve as a biomarker for poor prognosis, and is closely associated with enhanced immune cell infiltration and immune checkpoint expression in HCC. These findings suggest that DNMT1 may serve as a potential therapeutic target for both conventional treatment and immunotherapy in HCC patients.
- Open Access
- 30 September 2021
- Published by Springer Nature in Research Square
SNHG3/miR-148a-3p Axis–mediated High Expression of DNMT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma
Background Epigenetic reprogramming plays an important role in the occurrence, development, and prognosis of hepatocellular carcinoma (HCC). DNA methylation is a key epigenetic regulatory mechanism, and DNA methyltransferase 1 (DNMT1) is the major enzyme responsible for maintenance methylation. Nevertheless, the role and mechanism of DNMT1 in HCC remains poorly defined. Methods In the current study, we conducted pan-cancer analysis for DNMT1’s expression and prognosis using The Cancer Genome Atlas (TCGA) data set. We conducted gene Set Enrichment Analysis (GSEA) between high-and-low DNMT1 expression groups to identify DNMT1-related functional significance. We also investigated the relationship between DNMT1 expression and tumor immune microenvironment, including immune cell infiltration and the expression of immune checkpoints. Through a combination series of computer analyses (including expression analyses, correlation analyses, and survival analyses), the noncoding RNAs (ncRNAs) that contribute to the overexpression of DNMT1 were ultimately identified. Results We found that DNMT1 was upregulated in 16 types of human carcinoma including HCC, and DNMT1 might be a biomarker predicting unfavorable prognosis in HCC patients. DNMT1 mRNA expression was statistically associated with age, histological grade, and the level of serum AFP. Moreover, DNMT1 level was significantly and positively linked to tumor immune cell infiltration, immune cell biomarkers, and immune checkpoint expression. Meanwhile, Gene Set Enrichment Analysis (GSEA) revealed that high-DNMT1 expression was associated with epithelial mesenchymal transition (EMT), E2F target, G2M checkpoint, and inflammatory response. Finally, through a combination series of computer analyses the SNHG3/hsa-miR-148a-3p/DNMT1 axis was confirmed as the potential regulatory pathway in HCC. Conclusion SNHG3/miR-148a-3p axis upregulation of DNMT1 may be related to poor outcome, tumor immune infiltration, and regulated malignant properties in HCC.
- 30 September 2021
- Published by Springer Nature in Research Square
Open AccessSNHG3/miR-148a-3p Axis–mediated High Expression of DNMT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma
Background Epigenetic reprogramming plays an important role in the occurrence, development, and prognosis of hepatocellular carcinoma (HCC). DNA methylation is a key epigenetic regulatory mechanism, and DNA methyltransferase 1 (DNMT1) is the major enzyme responsible for maintenance methylation. Nevertheless, the role and mechanism of DNMT1 in HCC remains poorly defined. Methods In the current study, we conducted pan-cancer analysis for DNMT1’s expression and prognosis using The Cancer Genome Atlas (TCGA) data set. We conducted gene Set Enrichment Analysis (GSEA) between high-and-low DNMT1 expression groups to identify DNMT1-related functional significance. We also investigated the relationship between DNMT1 expression and tumor immune microenvironment, including immune cell infiltration and the expression of immune checkpoints. Through a combination series of computer analyses (including expression analyses, correlation analyses, and survival analyses), the noncoding RNAs (ncRNAs) that contribute to the overexpression of DNMT1 were ultimately identified. Results We found that DNMT1 was upregulated in 16 types of human carcinoma including HCC, and DNMT1 might be a biomarker predicting unfavorable prognosis in HCC patients. DNMT1 mRNA expression was statistically associated with age, histological grade, and the level of serum AFP. Moreover, DNMT1 level was significantly and positively linked to tumor immune cell infiltration, immune cell biomarkers, and immune checkpoint expression. Meanwhile, Gene Set Enrichment Analysis (GSEA) revealed that high-DNMT1 expression was associated with epithelial mesenchymal transition (EMT), E2F target, G2M checkpoint, and inflammatory response. Finally, through a combination series of computer analyses the SNHG3/hsa-miR-148a-3p/DNMT1 axis was confirmed as the potential regulatory pathway in HCC. Conclusion SNHG3/miR-148a-3p axis upregulation of DNMT1 may be related to poor outcome, tumor immune infiltration, and regulated malignant properties in HCC.
- Open Access
- 1 September 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (18) , 1443
CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma
Background: Increased evidence has indicated that the tumour microenvironment plays an essential in the development, treatment and prognosis of head and neck squamous cell carcinoma (HNSC). Recent studies have indicated CC chemokine receptor 4 (CCR4) plays an essential role in tumor invasion and other adverse biological behavior. This study used data from the Cancer Genome Atlas (TCGA) database to explore the role of CCR4 in HNSC and its clinical significance. Methods: The gene expression and clinical data of HNSC patients in the TCGA database were extracted. Gene Expression Profiling Interactive Analysis (GEPIA) was used to analyze the expression of CCR4 in tumor and non-tumor tissue. Kaplan-Meier survival analysis was used to analyze the relationship between CCR4 expression and overall survival rate (OS), disease-specific survival (DSS), and progression-free interval (PFI) in HNSC. A logistic regression model was used to analyze the relationships between various clinical factors and CCR4 expression. Gene Set Enrichment Analysis (GSEA) was used to explore the potential role of CCR4 in HNSC. Additionally, we explored the relationship between CCR4 and immune infiltration. Results: The expression of CCR4 in HNSC was not significantly different from that in normal tissue. The expression level of CCR4 in wild-type TP53 was higher than that in mutant TP53. Cox regression analysis showed the expression level of CCR4 was related to the patient's tumor grade and Tumor-Node-Metastasis (TNM) stage. CCR4 expression level is an independent prognostic factor. CCR4 is positively correlated with immune infiltration and immune checkpoints expression levels. The results of GSEA revealed that the high CCR4 expression group genes were enriched in allograft rejection, inflammatory response, IL-6/JAK/STAT3 signaling, interferon gamma response, and KRAS signaling up. Low CCR4 expression group genes were enriched in oxidative phosphorylation, MYC targets v1, DNA repair, reactive oxygen species pathway, and P53 pathway. Further, our study indicated CCR4 can also predict the prognosis of radiotherapy patients. Conclusions: Our study found that CCR4 was a prognostic marker related to HNSC immune infiltration, and patients with high expression of CCR4 had a better prognosis.
- 1 September 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (18) , 1443
Open AccessCCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma
Background: Increased evidence has indicated that the tumour microenvironment plays an essential in the development, treatment and prognosis of head and neck squamous cell carcinoma (HNSC). Recent studies have indicated CC chemokine receptor 4 (CCR4) plays an essential role in tumor invasion and other adverse biological behavior. This study used data from the Cancer Genome Atlas (TCGA) database to explore the role of CCR4 in HNSC and its clinical significance. Methods: The gene expression and clinical data of HNSC patients in the TCGA database were extracted. Gene Expression Profiling Interactive Analysis (GEPIA) was used to analyze the expression of CCR4 in tumor and non-tumor tissue. Kaplan-Meier survival analysis was used to analyze the relationship between CCR4 expression and overall survival rate (OS), disease-specific survival (DSS), and progression-free interval (PFI) in HNSC. A logistic regression model was used to analyze the relationships between various clinical factors and CCR4 expression. Gene Set Enrichment Analysis (GSEA) was used to explore the potential role of CCR4 in HNSC. Additionally, we explored the relationship between CCR4 and immune infiltration. Results: The expression of CCR4 in HNSC was not significantly different from that in normal tissue. The expression level of CCR4 in wild-type TP53 was higher than that in mutant TP53. Cox regression analysis showed the expression level of CCR4 was related to the patient's tumor grade and Tumor-Node-Metastasis (TNM) stage. CCR4 expression level is an independent prognostic factor. CCR4 is positively correlated with immune infiltration and immune checkpoints expression levels. The results of GSEA revealed that the high CCR4 expression group genes were enriched in allograft rejection, inflammatory response, IL-6/JAK/STAT3 signaling, interferon gamma response, and KRAS signaling up. Low CCR4 expression group genes were enriched in oxidative phosphorylation, MYC targets v1, DNA repair, reactive oxygen species pathway, and P53 pathway. Further, our study indicated CCR4 can also predict the prognosis of radiotherapy patients. Conclusions: Our study found that CCR4 was a prognostic marker related to HNSC immune infiltration, and patients with high expression of CCR4 had a better prognosis.
- 1 October 2020
- Published by Elsevier in Life Sciences
- Vol. 259, 118148
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells
- 1 October 2020
- Published by Elsevier in Life Sciences
- Vol. 259, 118148
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells
- 1 August 2012
- Published by Wolters Kluwer Health
- Vol. 20 (8) , 593-7
[Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma].
To investigate whether epigenetic alterations in the insulin-like growth factor-II (IGF-II) gene that cause differential transcription or expression are correlated with onset and severity of hepatocellular carcinoma (HCC). Patient-matched specimens of HCC, paracancerous, and non-cancerous tissues were collected from 40 primary liver cancer patients. Epigenetic alterations in the promoter (P3) sequence of the IGF-II gene were analyzed by methylation-specific PCR (MSP) and IGF-II transcription was measured by RT-PCR. IGF-II protein expression and clinicopathological features were assessed by immunohistochemistry and microscopic observation. The rate of IGF-II P3 methylation was significantly lower in HCC tissues (0%) than in paracancerous tissues (vs. 47.5%; x2 = 24.918, P less than 0.001) and non-cancerous tissues (vs. 100%; x2 = 80.000, P less than 0.001). IGF-II mRNA expression was significantly higher in HCC tissues (100%) than in paracancerous tissues (vs. 52.5%; x2 = 24.918, P less than 0.001) and non-cancerous tissues (vs. 0%; x2 = 80.000, P less than 0.001). IGF-II protein expression was significantly higher in HCC tissues (82.5%) than in paracancerous tissues (vs. 45.0%; x2 = 12.170, P less than 0.001) and non-cancerous tissues (vs. 0%; x2 = 56.170, P less than 0.001). IGF-II overexpression in HCC was significantly associated with degree of differentiation, extent of infiltrated serosa, size of tumor, and HBV-positive infection status. Epigenetic alterations in the IGF-II gene regulate its transcription and expression and are closely associated with HCC development and progression.
- 1 August 2012
- Published by Wolters Kluwer Health
- Vol. 20 (8) , 593-7
[Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma].
To investigate whether epigenetic alterations in the insulin-like growth factor-II (IGF-II) gene that cause differential transcription or expression are correlated with onset and severity of hepatocellular carcinoma (HCC). Patient-matched specimens of HCC, paracancerous, and non-cancerous tissues were collected from 40 primary liver cancer patients. Epigenetic alterations in the promoter (P3) sequence of the IGF-II gene were analyzed by methylation-specific PCR (MSP) and IGF-II transcription was measured by RT-PCR. IGF-II protein expression and clinicopathological features were assessed by immunohistochemistry and microscopic observation. The rate of IGF-II P3 methylation was significantly lower in HCC tissues (0%) than in paracancerous tissues (vs. 47.5%; x2 = 24.918, P less than 0.001) and non-cancerous tissues (vs. 100%; x2 = 80.000, P less than 0.001). IGF-II mRNA expression was significantly higher in HCC tissues (100%) than in paracancerous tissues (vs. 52.5%; x2 = 24.918, P less than 0.001) and non-cancerous tissues (vs. 0%; x2 = 80.000, P less than 0.001). IGF-II protein expression was significantly higher in HCC tissues (82.5%) than in paracancerous tissues (vs. 45.0%; x2 = 12.170, P less than 0.001) and non-cancerous tissues (vs. 0%; x2 = 56.170, P less than 0.001). IGF-II overexpression in HCC was significantly associated with degree of differentiation, extent of infiltrated serosa, size of tumor, and HBV-positive infection status. Epigenetic alterations in the IGF-II gene regulate its transcription and expression and are closely associated with HCC development and progression.